GSA Capital Partners’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-50,686
| Closed | -$733K | – | 1881 |
|
|
2026
Q1 | $733K | Buy |
+50,686
| New | +$727K | 0.05% | 665 |
|
|
2025
Q4 | – | Sell |
-51,247
| Closed | -$404K | – | 1798 |
|
|
2025
Q3 | $404K | Sell |
51,247
-5,930
| -10% | -$42.2K | 0.03% | 996 |
|
|
2025
Q2 | $328K | Sell |
57,177
-2,338
| -4% | -$15.1K | 0.02% | 1201 |
|
|
2025
Q1 | $486K | Sell |
59,515
-22,826
| -28% | -$211K | 0.04% | 824 |
|
|
2024
Q4 | $776K | Sell |
82,341
-51,459
| -38% | -$535K | 0.06% | 580 |
|
|
2024
Q3 | $1.43M | Buy |
133,800
+83,081
| +164% | +$905K | 0.11% | 250 |
|
|
2024
Q2 | $503K | Buy |
+50,719
| New | +$521K | 0.04% | 960 |
|
|
2023
Q1 | – | Sell |
-21,181
| Closed | -$259K | – | 1610 |
|
|
2022
Q4 | $259K | Buy |
+21,181
| New | +$238K | 0.03% | 1030 |
|
|
2022
Q3 | – | Sell |
-12,023
| Closed | -$129K | – | 1638 |
|
|
2022
Q2 | $129K | Buy |
+12,023
| New | +$99K | 0.02% | 1177 |
|
|
2021
Q4 | – | Sell |
-112,813
| Closed | -$1.08M | – | 1531 |
|
|
2021
Q3 | $1.08M | Buy |
+112,813
| New | +$1.15M | 0.11% | 279 |
|
|
2021
Q2 | – | Sell |
-56,077
| Closed | -$554K | – | 1400 |
|
|
2021
Q1 | $554K | Buy |
+56,077
| New | +$868K | 0.09% | 294 |
|
|
2020
Q4 | – | Sell |
-41,952
| Closed | -$592K | – | 1329 |
|
|
2020
Q3 | $592K | Buy |
+41,952
| New | +$611K | 0.1% | 302 |
|
|
2019
Q4 | – | Sell |
-13,370
| Closed | -$107K | – | 1525 |
|
|
2019
Q3 | $107K | Buy |
+13,370
| New | +$145K | 0.01% | 1269 |
|
|
2017
Q4 | – | Sell |
-20,506
| Closed | -$309K | – | 1638 |
|
|
2017
Q3 | $309K | Buy |
+20,506
| New | +$271K | 0.02% | 1224 |
|
Other funds holding FOLD
GSA Capital Partners's FOLD Position: Q2 2026 in Review
GSA Capital Partners sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 50,686 shares — an estimated $733K sold.
GSA Capital Partners first reported a position in FOLD in Q3 2017 and held it in 14 quarters. The position peaked at $1.43M in Q3 2024. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- GSA Capital Partners reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- GSA Capital Partners sold 50,686 Amicus Therapeutics shares in Q2 2026, an estimated $733K.
- GSA Capital Partners first reported a position in Amicus Therapeutics in Q3 2017 and held it in 14 quarters.
- GSA Capital Partners's Amicus Therapeutics position peaked at $1.43M in Q3 2024.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.